Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma.
Hannah E DzimitrowiczElizabeth EsterbergLaStella MilesGiovanni ZanottiAzah BorhamMichael R HarrisonPublished in: Cancer medicine (2021)
Despite increasing number of patients with locoregional RCC at high recurrence risk referred to medical oncologists after nephrectomy, few patients received AST, including participation in clinical trials. With increasing AST options and ongoing clinical trials in this space, these findings highlight the need for continued efforts at identifying effective AST and referring patients most likely to benefit to medical oncologists. ClinicalTrials.gov, NCT04309617.